SlideShare a Scribd company logo
SOAP FORMAT ON DVT & PE
From Prolonged Television
Watching
PRESENTED BY : Premal Vaghela
PATIENT’S DETAILS
• Name : ABC
• Age : 59 years
• Gender : Female
• Weight : -
• Height : -
• BMI : 51 kg/m²
• Mental status : -
HISTORY OF PRESENT ILLNESS
• She has past medical history of obesity , autoimmune hepatitis, and
osteoporosis presented to emergency department (ED).
• Complaining of right calf pain and swelling.
• She had no history of previous venous thromboembolic disease.
• The patient stated that the pain started after watching television for
eight continuous hours.
• The following day, she noted persistent right calf pain.
• However, she was particularly engaged in national convention coverage
and watched television continuously for approximately eight more
hours.
Cont….
• She recalls that she did not take any breaks from watching the convention
in fact she stated she only moves from the chair once to go to the
bathroom.
• After two days of mild throbbing pain and swelling , she decided to have
family members drive her to ED.
PAST MEDICAL HISTORY
• The patient has a history of immune hepatitis which had been stable for
years , treated with Imuran.
• Hiatal hernia (hiatal hernia occurs when the upper part of your stomach
bulges through the large muscle separating your abdomen and chest
(diaphragm).
• Sleep apnea requiring nighttime continuous positive airway pressure
(CPAP) machine.
• Osteoporosis.
PAST SURGICAL HISTORY
• She had no previous no surgeries other than a left wrist surgery 20 years
previously.
•PAST SOCIAL HISTORY
• She never smoked and She dose not drink alcohol.
FAMILY HISTORY
• The family history was notable for Paget’s disease (A disease that disrupts
the replacement of old bone tissue with new bone tissue)
• She denied any family history was
thromboembolism , bleeding , or clotting disorders
PAST MEDICATION HISTORY
• Other than Imuran (Azathioprine ; is an immunosuppressive medication)
and Fosamax (Alendronic acid ; is a bisphosphonate medication used to
treat osteoporosis and Paget's disease of bone) .
S : SUBJECTIVE
PATIENT’S COMPLAINTS :
• Chief complain : Persistent right calf pain
• She was having occasional dizziness and dyspnea on exertion
In patients undergoing general
and abdominal-pelvic surgeries,
the Caprini score is used to
assess the risk of DVT.
Interpretation of the Caprini
risk score
The Caprini score is calculated
by adding the scores of all
factors present in the patient.
The Caprini score is interpreted
in the following way:
Score 0–1: Low risk of VTE
Score 2: Moderate of VTE
Score 3–4: High risk of VTE
Score ≥5: Highest risk for VTE.
O : OBJECTIVE
EXAMINATION
GENERAL EXAMINATION:
• Blood pressure: 115/70 mmHg
• Heart rate: 125 bpm(60-100 bpm)
• Respiratory rate: 18 bpm(12-16
bpm)
• Temperature: 97.1 F
• Oxygen saturation :96%
SYSTEMIC EXAMINATION:
• Cardiac: no murmurs
• Pulmonary: Breath sounds were
diminished bilaterally.
• Liver function tests were
normal.
LAB INVESTIGATIONS
OTHER DIAGNOSTIC TEST
• Her pain score was 5/10 and she was anxious.
• On physical exam, the patient appeared mildly anxious with obvious
swelling of her right calf. There was moderate right calf tenderness
with +1 pitting edema(least severe type of edema).
Computed Tomography Angiography (CTA) of the chest was positive for
bilateral pulmonary emboli specifically right upper lobe, right middle lobe,
and left lower lobe segmental thrombi.
Ultrasound revealed occlusive thrombus to right
popliteal and right posterior tibial vein.
CONT..
• Anticoagulation with Thrombolytic was initiated in the ER with IV
heparin.
• She had a 2D echocardiogram that revealed mild right ventricular
dysfunction, mild tricuspid regurgitation, and an elevated pulmonary
artery pressure of 25–30 mmHg at rest.
• The pulmonary/critical team was consulted and given that the patient
had normal troponin, BNP, and oxygenation on RA.
• Additionally, the patient’s tachycardia improved with IV fluids.
A: ASSESSMENT
DIAGNOSIS
• On the basis of history , complaints of patient, Laboratory parameters
and other diagnostic test, we may conclude that patient is suffering
from DVT & PE from prolonged Television watching.
ETIOLOGY
• Have been inactive or immobile for long periods of time due to bed rest
or surgery.
• Have a personal or family history of a blood clotting disorder, such as
deep vein thrombosis (DVT) or pulmonary embolism (PE).
• Have a history of cancer or are receiving chemotherapy.
• Sit for prolonged periods.
• Smoking
NEED OF THERAPY
• To Reduce morbidity and mortality rates.
• To Resolve complaints of patient.
• To improve overall health status of patient.
• To prevent further complication of the disease.
• To improve patient’s quality of life.
ASSESSMENT OF STANDARD THERAPY
ASSESSMENT OF CURRENT THERAPY
1. Drug: Heparin
 Class: Anticoagulants
 Dose: -
 Frequency: -
 Route of administration: IV
 Indication: DVT & PE, Acute Coronary Syndromes
CONT..
M/A: Mechanism for low dose: Inactivates factor Xa and inhibits conversion of prothrombin to
thrombin
Mechanism for high dose: Inactivates factors IX, X, XI, and XII and thrombin and inhibits
conversion of fibrinogen to fibrin
• Also inhibits activation of factor VIII
A/E: Heparin-induced thrombocytopenia, possibly delayed (10-30% ), Mild pain ,Hemorrhage
,Injection site ulcer (after deep SC injection), Increased liver aminotransferase, Anaphylaxis,
Immune hypersensitivity reaction, Osteoporosis (long-term, high-dose use)
Contraindication : History of pentosan polysulfate-induced thrombocytopenia (HIT) (with or
without thrombosis),Uncontrolled, active bleeding (except DIC), Known hypersensitivity to heparin
NOTE : This drug is rational.
2. Drug: rivaroxaban
 Class: Anticoagulants, Factor Xa Inhibitors
 Dose: -
 Frequency:-
 Route of administration:
 Indication: stroke, atrial fibrillation, DVT and /or PE, venous
thromboembolism
CONT..
• M/A: Factor Xa inhibitor that inhibits platelet activation by selectively blocking the
active site of factor Xa without requiring a cofactor for activity ,Blood coagulation
cascade is dependent on the activation of factor X to factor Xa via the intrinsic and
extrinsic pathways, which play a central role in the blood coagulation cascade.
• A/E: Hematoma (<3%),Back pain (2.9%),Wound secretion (2.8%),Abdominal pain
(2.7%),Dizziness (2.2%),Pruritus (2.1-2.2%),Pain in extremity (1.7%), Insomnia
(1.6%),Anxiety (1.4%), Blister (1.4%),Fatigue (1.4%), Muscle spasm (1.3%),Syncope
(1.2%), Muscle spasm (1.2%),Depression (1.2%) ,Major bleeding
• Contraindication : Hypersensitivity ,Active pathological bleeding, Patients who have had
transcatheter aortic valve replacement.
NOTE: This drug is rational
PHARMACOKINETICS
P: Planning
Discharge medication
• Not given
GOAL OF THERAPY
 GENERAL GOALS
-To reduce the morbidity and
mortality rates.
- To improve patients quality of
life.
- To prevent further
complications.
 PATIENT SPECIFIC GOAL
- To provide the best possible
treatment to patient.
- To overcome the complaints of
the patient.
- To give the best treatment
whichever is possible.
MONITORING THERAPY
Drug Therapeutic monitoring Toxicity monitoring
Rivaroxaban The rivaroxaban assay
measures circulating levels of
rivaroxaban based on its
anticoagulant action. Measuring
rivaroxaban concentration will allow
dose adjustment to prevent too
much anticoagulant effect and risk
for bleeding or no anticoagulant
action and inadequate therapy.
Testing for Protein C, antithrombin
and fibrinogen activity should be
accurate on rivaroxaban. according
to bleeding risk - restart the drug 24
– 72 hours after a procedure.
-
DRUG-DRUG INTERACTION
POINTS TO PHYSICIAN
• There are improper documentation.
• Patient’s height and weight are not measured.
• No measurement of lipid levels, uric acid levels and thyroid hormone levels
is carried out.
• Keep the patient well hydrated as there are more chances of dehydration
because of blood loss due to injury and also it will be helpful for
improvement in patient’s blood pressure
POINTS TO PATIENT
 DISEASE RELATED:
• PE : Pulmonary embolism is when a
blood clot stuck in an artery in the
lung and blocks blood flow to the
lung.
• It usually arises from a thrombus
(clot) that originates in the deep
venous system of the lower
extremities.
DRUG RELATED
1) HEPARIN
Patient / Family education:
• Caution patient to avoid IM injections.
• Advise patient to avoid activities that carry risk of injury. Inform patient of potential for hair loss.
• Explain that this effect may occur several months after heparin therapy is started.
• Inform female patients that menstruation may be somewhat increased and prolonged.
• Advise patient that smoking and alcohol may alter response to heparin, and therefore, are not
advised.
• Inform patient that abrupt withdrawal of heparin may precipitate increased coagulability.
 ADMINISTRATION AND STORAGE
• Heparin is strongly acidic and is incompatible with many drugs.
• Avoid mixing any drug with heparin unless specifically advised by health care provider.
• Do not aspirate patient to check entry into blood vessel. Apply gentle pressure to puncture site for
about 1 min; do not massage. Rotate injection sites frequently and keep record.
• IV administration may be given undiluted over 1 min.
• For IV infusion, dilute prescribed amount in 0.9% Sodium Chloride for Injection, D5W, or Ringer's
Injection solution.
• Use infusion pump to ensure accuracy. Store at room temperature. Protect from freezing.
• Inspect all preparations for particulate matter prior to administration.
• Also inspect for discoloration; note that slight discoloration does not alter potency.
2) rivaroxaban
Patient / Family education:
• If you have difficulty swallowing the tablet whole, talk to your doctor
about other ways to take .
• Do not stop taking XARELTO without talking with your doctor first.. tell
your doctor if you go for any surgery,
• Take with or without food.
• Inform your healthcare provider if you have any symptoms like headache ,
pain, swelling or discomfort dizziness , nose bleeding bleeding of gums
 ADMINISTRATION AND STORAGE
• Keep all medicines out of the reach and sight of children.
• Store in a cool, dry place, away from direct heat and light.
• Store at room temperature between 68° F to 77°F (20° to 25° C).
LIFE STYLE MODIFICATION
• Stop smoking
• Loose weight if you are over weight and try to maintain healthy weight.
• Limiting the amount of time you spend sitting
• Exercise regularly mainly walking and move your legs to prevent the blood from
pooling.
• Avoid wearing tight-fitting clothes for extended periods
• Drinking lots of fluids
• Consuming foods that act as natural blood thinners to reduce the risk of developing
blood clots, such as vitamin E, ginger, cayenne pepper, garlic, turmeric, and cinnamon.
DIETARY MODIFICATIONS
• Limit unhealthy fats and sodium.
• Avoid sugary and processed foods.
• Eat more fruits and vegetables.
• Choose whole grains.
• Choose low-fat protein sources.
• Limit caffeine and alcohol.
• Healthy fats like olive and canola oil.
FOLLOW-UP AND REVIEW
• The patient was hemodynamically stable upon leaving the emergency
department for the ICU .
• She was transitioned over to novel anticoagulant rivaroxaban for
following day ( hospital day number 1 ) and was discharged home
three day later without complication.
REFERENCES
• Joseph T. DiPiro, Pharmacotherapy: A Pathophysiologic Approach, 10th
Edition, Mc Graw Hill Education.
• David S. Tatro, A to Z Drug Facts, Facts and Comparison.
• Leslie Kane (2018) Medscape, Available at www.Medscape.com (Last
Accessed on: 10th January 2020).
• https://www.webmd.com/dvt/foods-help-prevent-dvt.
• https://heartofdixieveincenter.com/lifestyle-choices-can-reduce-risk-
blood-clots/
Soap format on dvt

More Related Content

What's hot

Ward round participation
Ward round participationWard round participation
Ward round participation
Sarah Pulackal
 
Drug information center in a retail Drug Store
Drug information center in a retail Drug StoreDrug information center in a retail Drug Store
Drug information center in a retail Drug Store
Yamini Shah
 
8. pharmacotherapy
8. pharmacotherapy8. pharmacotherapy
8. pharmacotherapyGerika Aura
 
compliance” vs “adherence
compliance” vs “adherencecompliance” vs “adherence
compliance” vs “adherence
Moen Amgary
 
Drug information and poison information
Drug information and poison informationDrug information and poison information
Drug information and poison information
THUSHARA MOHAN
 
Clinical trial regulation 2019
Clinical trial regulation 2019Clinical trial regulation 2019
Clinical trial regulation 2019
swathijai
 
DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES
DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASESDRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES
DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES
Dr.Amreen Saba Attariya
 
Adr reporting ppt
Adr reporting pptAdr reporting ppt
Adr reporting ppt
RimaSingh14
 
Drug utilization evaluation
Drug utilization evaluationDrug utilization evaluation
Drug utilization evaluation
Dr. Ramesh Bhandari
 
Establishing a drug information center
Establishing a drug information centerEstablishing a drug information center
Establishing a drug information center
katta amulya
 
FDA-Fast Track Designation
FDA-Fast Track DesignationFDA-Fast Track Designation
FDA-Fast Track Designation
Vansh Raina
 
Ward Round Participation
Ward Round ParticipationWard Round Participation
Ward Round Participation
ISF COLLEGE OF PHARMACY MOGA
 
RADIATION POISONING (1).pptx
RADIATION POISONING (1).pptxRADIATION POISONING (1).pptx
RADIATION POISONING (1).pptx
Mamtanaagar1
 
Adverse drug reaction monitoring and reporting
Adverse drug reaction monitoring and reportingAdverse drug reaction monitoring and reporting
Adverse drug reaction monitoring and reporting
THUSHARA MOHAN
 
Protocol for tdm
Protocol for tdmProtocol for tdm
Protocol for tdm
SwarnaPriyaBasker
 
Prescription event monitoring- rumana hameed
Prescription event monitoring- rumana hameedPrescription event monitoring- rumana hameed
Prescription event monitoring- rumana hameed
Rumana Hameed
 
Management of adverse drug reactions
Management of adverse drug reactionsManagement of adverse drug reactions
Management of adverse drug reactions
ReshmaManeDeshmukh
 
Drug information centers
Drug information centersDrug information centers
Drug information centersNica Solis
 
Patient data analysis
Patient data analysisPatient data analysis
Patient data analysis
Rafi Bhat
 
Dose adjustment in Renal Disorders
Dose adjustment in Renal DisordersDose adjustment in Renal Disorders
Dose adjustment in Renal Disorders
Dr. Ramesh Bhandari
 

What's hot (20)

Ward round participation
Ward round participationWard round participation
Ward round participation
 
Drug information center in a retail Drug Store
Drug information center in a retail Drug StoreDrug information center in a retail Drug Store
Drug information center in a retail Drug Store
 
8. pharmacotherapy
8. pharmacotherapy8. pharmacotherapy
8. pharmacotherapy
 
compliance” vs “adherence
compliance” vs “adherencecompliance” vs “adherence
compliance” vs “adherence
 
Drug information and poison information
Drug information and poison informationDrug information and poison information
Drug information and poison information
 
Clinical trial regulation 2019
Clinical trial regulation 2019Clinical trial regulation 2019
Clinical trial regulation 2019
 
DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES
DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASESDRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES
DRUG-DOSE ADJUSTMENT IN PATIENTS WITH HEPATIC DISEASES
 
Adr reporting ppt
Adr reporting pptAdr reporting ppt
Adr reporting ppt
 
Drug utilization evaluation
Drug utilization evaluationDrug utilization evaluation
Drug utilization evaluation
 
Establishing a drug information center
Establishing a drug information centerEstablishing a drug information center
Establishing a drug information center
 
FDA-Fast Track Designation
FDA-Fast Track DesignationFDA-Fast Track Designation
FDA-Fast Track Designation
 
Ward Round Participation
Ward Round ParticipationWard Round Participation
Ward Round Participation
 
RADIATION POISONING (1).pptx
RADIATION POISONING (1).pptxRADIATION POISONING (1).pptx
RADIATION POISONING (1).pptx
 
Adverse drug reaction monitoring and reporting
Adverse drug reaction monitoring and reportingAdverse drug reaction monitoring and reporting
Adverse drug reaction monitoring and reporting
 
Protocol for tdm
Protocol for tdmProtocol for tdm
Protocol for tdm
 
Prescription event monitoring- rumana hameed
Prescription event monitoring- rumana hameedPrescription event monitoring- rumana hameed
Prescription event monitoring- rumana hameed
 
Management of adverse drug reactions
Management of adverse drug reactionsManagement of adverse drug reactions
Management of adverse drug reactions
 
Drug information centers
Drug information centersDrug information centers
Drug information centers
 
Patient data analysis
Patient data analysisPatient data analysis
Patient data analysis
 
Dose adjustment in Renal Disorders
Dose adjustment in Renal DisordersDose adjustment in Renal Disorders
Dose adjustment in Renal Disorders
 

Similar to Soap format on dvt

231019 Anticoagulant reviseGGGGGGGGGGG pptx
231019 Anticoagulant reviseGGGGGGGGGGG pptx231019 Anticoagulant reviseGGGGGGGGGGG pptx
231019 Anticoagulant reviseGGGGGGGGGGG pptx
MyThaoAiDoan
 
Case presentation on dvt (1)
Case presentation on dvt (1)Case presentation on dvt (1)
Case presentation on dvt (1)
Vishali Vishu
 
Deep Vein Thrombosis
Deep Vein ThrombosisDeep Vein Thrombosis
Deep Vein Thrombosisdbridley
 
Hepatoma.pptx
Hepatoma.pptxHepatoma.pptx
Hepatoma.pptx
NoshirwanGazder
 
Treatment of venous thrombosis and pulmonary embolism
Treatment of venous thrombosis and pulmonary embolism Treatment of venous thrombosis and pulmonary embolism
Treatment of venous thrombosis and pulmonary embolism
Mahmoud Elhusseiny Abolmagd
 
Hypertension Emergencies and their managementpptx
Hypertension Emergencies and their managementpptxHypertension Emergencies and their managementpptx
Hypertension Emergencies and their managementpptx
UzomaBende
 
Deep vein thrombosis
Deep vein thrombosisDeep vein thrombosis
Deep vein thrombosis
Dr. Sandesh Shrestha
 
Deep Vein Thrombosis
Deep Vein ThrombosisDeep Vein Thrombosis
Deep Vein Thrombosisdbridley
 
Venous thromboembolism
Venous thromboembolismVenous thromboembolism
Venous thromboembolism
ZeelNaik2
 
Covid 19 management update - Sohag Heart Center Experience
Covid 19 management update - Sohag Heart Center ExperienceCovid 19 management update - Sohag Heart Center Experience
Covid 19 management update - Sohag Heart Center Experience
Emad Qasem
 
Turp CASE FINAL.pptx
Turp CASE FINAL.pptxTurp CASE FINAL.pptx
Turp CASE FINAL.pptx
JeyRaj4
 
Management of upper gi bleed
Management of upper gi bleedManagement of upper gi bleed
Management of upper gi bleed
Taimoor666
 
Anticoagulation therapy for atrial fibrillation
Anticoagulation therapy for atrial fibrillationAnticoagulation therapy for atrial fibrillation
Anticoagulation therapy for atrial fibrillation
Lyndon Woytuck
 
Case presentation ICH & Prosthetic MV
Case presentation ICH & Prosthetic MVCase presentation ICH & Prosthetic MV
Case presentation ICH & Prosthetic MVKamal Mergani
 
Case presentation Urosepsis
Case presentation UrosepsisCase presentation Urosepsis
Case presentation Urosepsis
tbf413
 
RESISTANT HYPERTENSION
RESISTANT HYPERTENSIONRESISTANT HYPERTENSION
RESISTANT HYPERTENSION
Dr Siva subramaniyan
 
Case presentation on MYOCARDIAL INFARCTION
Case presentation on MYOCARDIAL INFARCTIONCase presentation on MYOCARDIAL INFARCTION
Case presentation on MYOCARDIAL INFARCTION
Vigneswari Paladugu
 
Turp CASE FINAL.pdf
Turp CASE FINAL.pdfTurp CASE FINAL.pdf
Turp CASE FINAL.pdf
BansariShah44
 

Similar to Soap format on dvt (20)

231019 Anticoagulant reviseGGGGGGGGGGG pptx
231019 Anticoagulant reviseGGGGGGGGGGG pptx231019 Anticoagulant reviseGGGGGGGGGGG pptx
231019 Anticoagulant reviseGGGGGGGGGGG pptx
 
Case presentation on dvt (1)
Case presentation on dvt (1)Case presentation on dvt (1)
Case presentation on dvt (1)
 
Deep Vein Thrombosis
Deep Vein ThrombosisDeep Vein Thrombosis
Deep Vein Thrombosis
 
Hepatoma.pptx
Hepatoma.pptxHepatoma.pptx
Hepatoma.pptx
 
Treatment of venous thrombosis and pulmonary embolism
Treatment of venous thrombosis and pulmonary embolism Treatment of venous thrombosis and pulmonary embolism
Treatment of venous thrombosis and pulmonary embolism
 
Hypertension Emergencies and their managementpptx
Hypertension Emergencies and their managementpptxHypertension Emergencies and their managementpptx
Hypertension Emergencies and their managementpptx
 
Deep vein thrombosis
Deep vein thrombosisDeep vein thrombosis
Deep vein thrombosis
 
Deep Vein Thrombosis
Deep Vein ThrombosisDeep Vein Thrombosis
Deep Vein Thrombosis
 
Obstetric embolism
Obstetric embolismObstetric embolism
Obstetric embolism
 
Venous thromboembolism
Venous thromboembolismVenous thromboembolism
Venous thromboembolism
 
Covid 19 management update - Sohag Heart Center Experience
Covid 19 management update - Sohag Heart Center ExperienceCovid 19 management update - Sohag Heart Center Experience
Covid 19 management update - Sohag Heart Center Experience
 
Turp CASE FINAL.pptx
Turp CASE FINAL.pptxTurp CASE FINAL.pptx
Turp CASE FINAL.pptx
 
Management of upper gi bleed
Management of upper gi bleedManagement of upper gi bleed
Management of upper gi bleed
 
Anticoagulation therapy for atrial fibrillation
Anticoagulation therapy for atrial fibrillationAnticoagulation therapy for atrial fibrillation
Anticoagulation therapy for atrial fibrillation
 
Case presentation ICH & Prosthetic MV
Case presentation ICH & Prosthetic MVCase presentation ICH & Prosthetic MV
Case presentation ICH & Prosthetic MV
 
Case presentation Urosepsis
Case presentation UrosepsisCase presentation Urosepsis
Case presentation Urosepsis
 
N334 ACR Hammond
N334 ACR HammondN334 ACR Hammond
N334 ACR Hammond
 
RESISTANT HYPERTENSION
RESISTANT HYPERTENSIONRESISTANT HYPERTENSION
RESISTANT HYPERTENSION
 
Case presentation on MYOCARDIAL INFARCTION
Case presentation on MYOCARDIAL INFARCTIONCase presentation on MYOCARDIAL INFARCTION
Case presentation on MYOCARDIAL INFARCTION
 
Turp CASE FINAL.pdf
Turp CASE FINAL.pdfTurp CASE FINAL.pdf
Turp CASE FINAL.pdf
 

Recently uploaded

GBSN- Microbiology (Lab 3) Gram Staining
GBSN- Microbiology (Lab 3) Gram StainingGBSN- Microbiology (Lab 3) Gram Staining
GBSN- Microbiology (Lab 3) Gram Staining
Areesha Ahmad
 
GBSN - Biochemistry (Unit 5) Chemistry of Lipids
GBSN - Biochemistry (Unit 5) Chemistry of LipidsGBSN - Biochemistry (Unit 5) Chemistry of Lipids
GBSN - Biochemistry (Unit 5) Chemistry of Lipids
Areesha Ahmad
 
Multi-source connectivity as the driver of solar wind variability in the heli...
Multi-source connectivity as the driver of solar wind variability in the heli...Multi-source connectivity as the driver of solar wind variability in the heli...
Multi-source connectivity as the driver of solar wind variability in the heli...
Sérgio Sacani
 
Unveiling the Energy Potential of Marshmallow Deposits.pdf
Unveiling the Energy Potential of Marshmallow Deposits.pdfUnveiling the Energy Potential of Marshmallow Deposits.pdf
Unveiling the Energy Potential of Marshmallow Deposits.pdf
Erdal Coalmaker
 
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...
Sérgio Sacani
 
Richard's aventures in two entangled wonderlands
Richard's aventures in two entangled wonderlandsRichard's aventures in two entangled wonderlands
Richard's aventures in two entangled wonderlands
Richard Gill
 
NuGOweek 2024 Ghent - programme - final version
NuGOweek 2024 Ghent - programme - final versionNuGOweek 2024 Ghent - programme - final version
NuGOweek 2024 Ghent - programme - final version
pablovgd
 
role of pramana in research.pptx in science
role of pramana in research.pptx in sciencerole of pramana in research.pptx in science
role of pramana in research.pptx in science
sonaliswain16
 
What is greenhouse gasses and how many gasses are there to affect the Earth.
What is greenhouse gasses and how many gasses are there to affect the Earth.What is greenhouse gasses and how many gasses are there to affect the Earth.
What is greenhouse gasses and how many gasses are there to affect the Earth.
moosaasad1975
 
insect taxonomy importance systematics and classification
insect taxonomy importance systematics and classificationinsect taxonomy importance systematics and classification
insect taxonomy importance systematics and classification
anitaento25
 
Cancer cell metabolism: special Reference to Lactate Pathway
Cancer cell metabolism: special Reference to Lactate PathwayCancer cell metabolism: special Reference to Lactate Pathway
Cancer cell metabolism: special Reference to Lactate Pathway
AADYARAJPANDEY1
 
Structural Classification Of Protein (SCOP)
Structural Classification Of Protein  (SCOP)Structural Classification Of Protein  (SCOP)
Structural Classification Of Protein (SCOP)
aishnasrivastava
 
Hemoglobin metabolism_pathophysiology.pptx
Hemoglobin metabolism_pathophysiology.pptxHemoglobin metabolism_pathophysiology.pptx
Hemoglobin metabolism_pathophysiology.pptx
muralinath2
 
Seminar of U.V. Spectroscopy by SAMIR PANDA
 Seminar of U.V. Spectroscopy by SAMIR PANDA Seminar of U.V. Spectroscopy by SAMIR PANDA
Seminar of U.V. Spectroscopy by SAMIR PANDA
SAMIR PANDA
 
Leaf Initiation, Growth and Differentiation.pdf
Leaf Initiation, Growth and Differentiation.pdfLeaf Initiation, Growth and Differentiation.pdf
Leaf Initiation, Growth and Differentiation.pdf
RenuJangid3
 
in vitro propagation of plants lecture note.pptx
in vitro propagation of plants lecture note.pptxin vitro propagation of plants lecture note.pptx
in vitro propagation of plants lecture note.pptx
yusufzako14
 
SCHIZOPHRENIA Disorder/ Brain Disorder.pdf
SCHIZOPHRENIA Disorder/ Brain Disorder.pdfSCHIZOPHRENIA Disorder/ Brain Disorder.pdf
SCHIZOPHRENIA Disorder/ Brain Disorder.pdf
SELF-EXPLANATORY
 
Hemostasis_importance& clinical significance.pptx
Hemostasis_importance& clinical significance.pptxHemostasis_importance& clinical significance.pptx
Hemostasis_importance& clinical significance.pptx
muralinath2
 
platelets_clotting_biogenesis.clot retractionpptx
platelets_clotting_biogenesis.clot retractionpptxplatelets_clotting_biogenesis.clot retractionpptx
platelets_clotting_biogenesis.clot retractionpptx
muralinath2
 
Body fluids_tonicity_dehydration_hypovolemia_hypervolemia.pptx
Body fluids_tonicity_dehydration_hypovolemia_hypervolemia.pptxBody fluids_tonicity_dehydration_hypovolemia_hypervolemia.pptx
Body fluids_tonicity_dehydration_hypovolemia_hypervolemia.pptx
muralinath2
 

Recently uploaded (20)

GBSN- Microbiology (Lab 3) Gram Staining
GBSN- Microbiology (Lab 3) Gram StainingGBSN- Microbiology (Lab 3) Gram Staining
GBSN- Microbiology (Lab 3) Gram Staining
 
GBSN - Biochemistry (Unit 5) Chemistry of Lipids
GBSN - Biochemistry (Unit 5) Chemistry of LipidsGBSN - Biochemistry (Unit 5) Chemistry of Lipids
GBSN - Biochemistry (Unit 5) Chemistry of Lipids
 
Multi-source connectivity as the driver of solar wind variability in the heli...
Multi-source connectivity as the driver of solar wind variability in the heli...Multi-source connectivity as the driver of solar wind variability in the heli...
Multi-source connectivity as the driver of solar wind variability in the heli...
 
Unveiling the Energy Potential of Marshmallow Deposits.pdf
Unveiling the Energy Potential of Marshmallow Deposits.pdfUnveiling the Energy Potential of Marshmallow Deposits.pdf
Unveiling the Energy Potential of Marshmallow Deposits.pdf
 
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...
 
Richard's aventures in two entangled wonderlands
Richard's aventures in two entangled wonderlandsRichard's aventures in two entangled wonderlands
Richard's aventures in two entangled wonderlands
 
NuGOweek 2024 Ghent - programme - final version
NuGOweek 2024 Ghent - programme - final versionNuGOweek 2024 Ghent - programme - final version
NuGOweek 2024 Ghent - programme - final version
 
role of pramana in research.pptx in science
role of pramana in research.pptx in sciencerole of pramana in research.pptx in science
role of pramana in research.pptx in science
 
What is greenhouse gasses and how many gasses are there to affect the Earth.
What is greenhouse gasses and how many gasses are there to affect the Earth.What is greenhouse gasses and how many gasses are there to affect the Earth.
What is greenhouse gasses and how many gasses are there to affect the Earth.
 
insect taxonomy importance systematics and classification
insect taxonomy importance systematics and classificationinsect taxonomy importance systematics and classification
insect taxonomy importance systematics and classification
 
Cancer cell metabolism: special Reference to Lactate Pathway
Cancer cell metabolism: special Reference to Lactate PathwayCancer cell metabolism: special Reference to Lactate Pathway
Cancer cell metabolism: special Reference to Lactate Pathway
 
Structural Classification Of Protein (SCOP)
Structural Classification Of Protein  (SCOP)Structural Classification Of Protein  (SCOP)
Structural Classification Of Protein (SCOP)
 
Hemoglobin metabolism_pathophysiology.pptx
Hemoglobin metabolism_pathophysiology.pptxHemoglobin metabolism_pathophysiology.pptx
Hemoglobin metabolism_pathophysiology.pptx
 
Seminar of U.V. Spectroscopy by SAMIR PANDA
 Seminar of U.V. Spectroscopy by SAMIR PANDA Seminar of U.V. Spectroscopy by SAMIR PANDA
Seminar of U.V. Spectroscopy by SAMIR PANDA
 
Leaf Initiation, Growth and Differentiation.pdf
Leaf Initiation, Growth and Differentiation.pdfLeaf Initiation, Growth and Differentiation.pdf
Leaf Initiation, Growth and Differentiation.pdf
 
in vitro propagation of plants lecture note.pptx
in vitro propagation of plants lecture note.pptxin vitro propagation of plants lecture note.pptx
in vitro propagation of plants lecture note.pptx
 
SCHIZOPHRENIA Disorder/ Brain Disorder.pdf
SCHIZOPHRENIA Disorder/ Brain Disorder.pdfSCHIZOPHRENIA Disorder/ Brain Disorder.pdf
SCHIZOPHRENIA Disorder/ Brain Disorder.pdf
 
Hemostasis_importance& clinical significance.pptx
Hemostasis_importance& clinical significance.pptxHemostasis_importance& clinical significance.pptx
Hemostasis_importance& clinical significance.pptx
 
platelets_clotting_biogenesis.clot retractionpptx
platelets_clotting_biogenesis.clot retractionpptxplatelets_clotting_biogenesis.clot retractionpptx
platelets_clotting_biogenesis.clot retractionpptx
 
Body fluids_tonicity_dehydration_hypovolemia_hypervolemia.pptx
Body fluids_tonicity_dehydration_hypovolemia_hypervolemia.pptxBody fluids_tonicity_dehydration_hypovolemia_hypervolemia.pptx
Body fluids_tonicity_dehydration_hypovolemia_hypervolemia.pptx
 

Soap format on dvt

  • 1. SOAP FORMAT ON DVT & PE From Prolonged Television Watching PRESENTED BY : Premal Vaghela
  • 2. PATIENT’S DETAILS • Name : ABC • Age : 59 years • Gender : Female • Weight : - • Height : - • BMI : 51 kg/m² • Mental status : -
  • 3. HISTORY OF PRESENT ILLNESS • She has past medical history of obesity , autoimmune hepatitis, and osteoporosis presented to emergency department (ED). • Complaining of right calf pain and swelling. • She had no history of previous venous thromboembolic disease. • The patient stated that the pain started after watching television for eight continuous hours. • The following day, she noted persistent right calf pain. • However, she was particularly engaged in national convention coverage and watched television continuously for approximately eight more hours.
  • 4. Cont…. • She recalls that she did not take any breaks from watching the convention in fact she stated she only moves from the chair once to go to the bathroom. • After two days of mild throbbing pain and swelling , she decided to have family members drive her to ED.
  • 5. PAST MEDICAL HISTORY • The patient has a history of immune hepatitis which had been stable for years , treated with Imuran. • Hiatal hernia (hiatal hernia occurs when the upper part of your stomach bulges through the large muscle separating your abdomen and chest (diaphragm). • Sleep apnea requiring nighttime continuous positive airway pressure (CPAP) machine. • Osteoporosis.
  • 6. PAST SURGICAL HISTORY • She had no previous no surgeries other than a left wrist surgery 20 years previously. •PAST SOCIAL HISTORY • She never smoked and She dose not drink alcohol.
  • 7. FAMILY HISTORY • The family history was notable for Paget’s disease (A disease that disrupts the replacement of old bone tissue with new bone tissue) • She denied any family history was thromboembolism , bleeding , or clotting disorders
  • 8. PAST MEDICATION HISTORY • Other than Imuran (Azathioprine ; is an immunosuppressive medication) and Fosamax (Alendronic acid ; is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone) .
  • 10. PATIENT’S COMPLAINTS : • Chief complain : Persistent right calf pain • She was having occasional dizziness and dyspnea on exertion
  • 11. In patients undergoing general and abdominal-pelvic surgeries, the Caprini score is used to assess the risk of DVT. Interpretation of the Caprini risk score The Caprini score is calculated by adding the scores of all factors present in the patient. The Caprini score is interpreted in the following way: Score 0–1: Low risk of VTE Score 2: Moderate of VTE Score 3–4: High risk of VTE Score ≥5: Highest risk for VTE.
  • 13. EXAMINATION GENERAL EXAMINATION: • Blood pressure: 115/70 mmHg • Heart rate: 125 bpm(60-100 bpm) • Respiratory rate: 18 bpm(12-16 bpm) • Temperature: 97.1 F • Oxygen saturation :96% SYSTEMIC EXAMINATION: • Cardiac: no murmurs • Pulmonary: Breath sounds were diminished bilaterally. • Liver function tests were normal.
  • 15. OTHER DIAGNOSTIC TEST • Her pain score was 5/10 and she was anxious. • On physical exam, the patient appeared mildly anxious with obvious swelling of her right calf. There was moderate right calf tenderness with +1 pitting edema(least severe type of edema).
  • 16. Computed Tomography Angiography (CTA) of the chest was positive for bilateral pulmonary emboli specifically right upper lobe, right middle lobe, and left lower lobe segmental thrombi.
  • 17. Ultrasound revealed occlusive thrombus to right popliteal and right posterior tibial vein.
  • 18. CONT.. • Anticoagulation with Thrombolytic was initiated in the ER with IV heparin. • She had a 2D echocardiogram that revealed mild right ventricular dysfunction, mild tricuspid regurgitation, and an elevated pulmonary artery pressure of 25–30 mmHg at rest. • The pulmonary/critical team was consulted and given that the patient had normal troponin, BNP, and oxygenation on RA. • Additionally, the patient’s tachycardia improved with IV fluids.
  • 20. DIAGNOSIS • On the basis of history , complaints of patient, Laboratory parameters and other diagnostic test, we may conclude that patient is suffering from DVT & PE from prolonged Television watching.
  • 21. ETIOLOGY • Have been inactive or immobile for long periods of time due to bed rest or surgery. • Have a personal or family history of a blood clotting disorder, such as deep vein thrombosis (DVT) or pulmonary embolism (PE). • Have a history of cancer or are receiving chemotherapy. • Sit for prolonged periods. • Smoking
  • 22. NEED OF THERAPY • To Reduce morbidity and mortality rates. • To Resolve complaints of patient. • To improve overall health status of patient. • To prevent further complication of the disease. • To improve patient’s quality of life.
  • 24.
  • 26. 1. Drug: Heparin  Class: Anticoagulants  Dose: -  Frequency: -  Route of administration: IV  Indication: DVT & PE, Acute Coronary Syndromes
  • 27. CONT.. M/A: Mechanism for low dose: Inactivates factor Xa and inhibits conversion of prothrombin to thrombin Mechanism for high dose: Inactivates factors IX, X, XI, and XII and thrombin and inhibits conversion of fibrinogen to fibrin • Also inhibits activation of factor VIII A/E: Heparin-induced thrombocytopenia, possibly delayed (10-30% ), Mild pain ,Hemorrhage ,Injection site ulcer (after deep SC injection), Increased liver aminotransferase, Anaphylaxis, Immune hypersensitivity reaction, Osteoporosis (long-term, high-dose use) Contraindication : History of pentosan polysulfate-induced thrombocytopenia (HIT) (with or without thrombosis),Uncontrolled, active bleeding (except DIC), Known hypersensitivity to heparin NOTE : This drug is rational.
  • 28. 2. Drug: rivaroxaban  Class: Anticoagulants, Factor Xa Inhibitors  Dose: -  Frequency:-  Route of administration:  Indication: stroke, atrial fibrillation, DVT and /or PE, venous thromboembolism
  • 29. CONT.. • M/A: Factor Xa inhibitor that inhibits platelet activation by selectively blocking the active site of factor Xa without requiring a cofactor for activity ,Blood coagulation cascade is dependent on the activation of factor X to factor Xa via the intrinsic and extrinsic pathways, which play a central role in the blood coagulation cascade. • A/E: Hematoma (<3%),Back pain (2.9%),Wound secretion (2.8%),Abdominal pain (2.7%),Dizziness (2.2%),Pruritus (2.1-2.2%),Pain in extremity (1.7%), Insomnia (1.6%),Anxiety (1.4%), Blister (1.4%),Fatigue (1.4%), Muscle spasm (1.3%),Syncope (1.2%), Muscle spasm (1.2%),Depression (1.2%) ,Major bleeding • Contraindication : Hypersensitivity ,Active pathological bleeding, Patients who have had transcatheter aortic valve replacement. NOTE: This drug is rational
  • 33. GOAL OF THERAPY  GENERAL GOALS -To reduce the morbidity and mortality rates. - To improve patients quality of life. - To prevent further complications.  PATIENT SPECIFIC GOAL - To provide the best possible treatment to patient. - To overcome the complaints of the patient. - To give the best treatment whichever is possible.
  • 35. Drug Therapeutic monitoring Toxicity monitoring Rivaroxaban The rivaroxaban assay measures circulating levels of rivaroxaban based on its anticoagulant action. Measuring rivaroxaban concentration will allow dose adjustment to prevent too much anticoagulant effect and risk for bleeding or no anticoagulant action and inadequate therapy. Testing for Protein C, antithrombin and fibrinogen activity should be accurate on rivaroxaban. according to bleeding risk - restart the drug 24 – 72 hours after a procedure. -
  • 37. POINTS TO PHYSICIAN • There are improper documentation. • Patient’s height and weight are not measured. • No measurement of lipid levels, uric acid levels and thyroid hormone levels is carried out. • Keep the patient well hydrated as there are more chances of dehydration because of blood loss due to injury and also it will be helpful for improvement in patient’s blood pressure
  • 38. POINTS TO PATIENT  DISEASE RELATED: • PE : Pulmonary embolism is when a blood clot stuck in an artery in the lung and blocks blood flow to the lung. • It usually arises from a thrombus (clot) that originates in the deep venous system of the lower extremities.
  • 39. DRUG RELATED 1) HEPARIN Patient / Family education: • Caution patient to avoid IM injections. • Advise patient to avoid activities that carry risk of injury. Inform patient of potential for hair loss. • Explain that this effect may occur several months after heparin therapy is started. • Inform female patients that menstruation may be somewhat increased and prolonged. • Advise patient that smoking and alcohol may alter response to heparin, and therefore, are not advised. • Inform patient that abrupt withdrawal of heparin may precipitate increased coagulability.
  • 40.  ADMINISTRATION AND STORAGE • Heparin is strongly acidic and is incompatible with many drugs. • Avoid mixing any drug with heparin unless specifically advised by health care provider. • Do not aspirate patient to check entry into blood vessel. Apply gentle pressure to puncture site for about 1 min; do not massage. Rotate injection sites frequently and keep record. • IV administration may be given undiluted over 1 min. • For IV infusion, dilute prescribed amount in 0.9% Sodium Chloride for Injection, D5W, or Ringer's Injection solution. • Use infusion pump to ensure accuracy. Store at room temperature. Protect from freezing. • Inspect all preparations for particulate matter prior to administration. • Also inspect for discoloration; note that slight discoloration does not alter potency.
  • 41. 2) rivaroxaban Patient / Family education: • If you have difficulty swallowing the tablet whole, talk to your doctor about other ways to take . • Do not stop taking XARELTO without talking with your doctor first.. tell your doctor if you go for any surgery, • Take with or without food. • Inform your healthcare provider if you have any symptoms like headache , pain, swelling or discomfort dizziness , nose bleeding bleeding of gums
  • 42.  ADMINISTRATION AND STORAGE • Keep all medicines out of the reach and sight of children. • Store in a cool, dry place, away from direct heat and light. • Store at room temperature between 68° F to 77°F (20° to 25° C).
  • 43. LIFE STYLE MODIFICATION • Stop smoking • Loose weight if you are over weight and try to maintain healthy weight. • Limiting the amount of time you spend sitting • Exercise regularly mainly walking and move your legs to prevent the blood from pooling. • Avoid wearing tight-fitting clothes for extended periods • Drinking lots of fluids • Consuming foods that act as natural blood thinners to reduce the risk of developing blood clots, such as vitamin E, ginger, cayenne pepper, garlic, turmeric, and cinnamon.
  • 44. DIETARY MODIFICATIONS • Limit unhealthy fats and sodium. • Avoid sugary and processed foods. • Eat more fruits and vegetables. • Choose whole grains. • Choose low-fat protein sources. • Limit caffeine and alcohol. • Healthy fats like olive and canola oil.
  • 45. FOLLOW-UP AND REVIEW • The patient was hemodynamically stable upon leaving the emergency department for the ICU . • She was transitioned over to novel anticoagulant rivaroxaban for following day ( hospital day number 1 ) and was discharged home three day later without complication.
  • 46. REFERENCES • Joseph T. DiPiro, Pharmacotherapy: A Pathophysiologic Approach, 10th Edition, Mc Graw Hill Education. • David S. Tatro, A to Z Drug Facts, Facts and Comparison. • Leslie Kane (2018) Medscape, Available at www.Medscape.com (Last Accessed on: 10th January 2020). • https://www.webmd.com/dvt/foods-help-prevent-dvt. • https://heartofdixieveincenter.com/lifestyle-choices-can-reduce-risk- blood-clots/